Breast cancer: A multidisciplinary approach to imaging in neoadjuvant treatment

M. Lobbes, Sittard-Geleen/NL (Radiologist)
M.L. Smidt, Maastricht/NL (Surgeon)
November 11, 2019
18:00 CET

Free of charge for active members of EUSOBI!

Webinar overview
Imaging of breast cancer patients treated with neoadjuvant chemotherapy influences treatment decision and impacts patient’s outcome. In this clinical decision-making process, imaging plays a pivotal role, with various modalities (such as(contrast-enhanced) mammography, tomosynthesis, ultrasound and breast MRI) being at the disposal of the radiologist. Every modality has its strengths and weaknesses in terms of response monitoring of patients treated with neoadjuvant chemotherapy. It is essential that all involved clinicians are aware of these, but also know how these findings impact clinical decision making. This joint ESOI/ESSO/EUSOBI webinar approaches imaging from a multidisciplinary view. Attendees will learn about multidisciplinary team management, the relevant questions from clinicians and how radiologists can answer these by applying different techniques. Short lectures will be followed by case-based discussions among the teachers and attendees, in this way simulating a multidisciplinary meeting.

About the speakers
Dr. Marc Lobbes is the director of the breast imaging center of the Zuyderland Medical Center in Sittard-Geleen, the Netherlands. He has an extensive expertise in all areas of breast imaging, including mammography, tomosynthesis, ultrasound, interventions and breast MRI, including breast PET-MRI. Dr. Lobbes was the first radiologist in the Netherlands to apply contrast-enhanced mammography and has published multiple scientific publications on this topic, including several book chapters. His primary research focus is the application of machine learning in (breast) oncologic imaging, the clinical implementation of contrast-enhanced mammography and MR imaging of the breast and axilla (the latter in close collaboration with dr. Smidt). He is an active member of the Dutch Society of Breast Imaging, member of the scientific counsel of the Dutch Expert Center for Screening and educational board member of the European Society of Breast Imaging (EUSOBI).

Dr. Marjolein Smidt is associate professor surgical oncology at the Maastricht University Medical Centre in Maastricht, The Netherlands, where she co-chairs the Comprehensive Cancer Centre as well as presides GROW research school’s program 2 concerning clinical research. Amongst others, she is a member of the SSO and ESSO scientific program committee and board member of UEMS on breast cancer surgery, which organizes the European exams on breast cancer surgery.
She has extensive knowledge in the field of breast cancer surgery and research.
“During the last decades, breast cancer survival increased impressively as a consequence of early detection and extensive adjuvant treatment. Consequently attention shifted from only aiming survival to a combined and patient-tailored endpoint including both survival as well as reducing morbidity, thereby improving quality of life. As a result of this attention shift, the question arose: “Which treatment is no longer necessary anymore?”. From a surgical point of view this means “Less invasive, equally safe” thereby limiting morbidity resulting from the extensive adjuvant treatment universal package deals. Concerning axillary treatment, the ultimate goal is axillary treatment which is equally safe in outcome (DFS) though less invasive and consequently results in less lifelong morbidity. This research line started with noninvasive nodal staging study with contrast enhanced MRI. This MRI offered comparable axillary knowledge as the sentinel biopsy, however without operating. Since the contrast was taken off-market, our search for a noninvasive imaging continued. Currently we are exploring the potential of PET-MR for nodal (re)staging in breast cancer patients.

This webinar is open to active ESOI, ESSO and EUSOBI members.
Please note that ESOI reserves the right to contact the ESSO and EUSOBI Offices to check for valid membership when you register via the below link.
Besides, due to the limit of 500 parallel attendees during the live session registrations will be accepted on a first come first serve basis.
In order to register please ensure your active membership with at least one society and complete the online registration: